Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Novel immunotherapies for rheumatoid arthritis.

Literature DB >> 23908512

Novel immunotherapies for rheumatoid arthritis.

Sarah Richardson¹, John Isaacs.
1. Newcastle University, UK.

Abstract

Entities: Chemical

Keywords: Rheumatoid arthritis; antidrug antibodies; biosimilars; immunotherapies; personalised medicine

Mesh：

Substances：

Year: 2013 PMID： 23908512 PMCID： PMC4954309 DOI： 10.7861/clinmedicine.13-4-391

Source DB: PubMed Journal: Clin Med (Lond) ISSN： 1470-2118 Impact factor: 2.659

× No keyword cloud information.

21 in total

Review 1. The role of biosimilars in the treatment of rheumatic diseases.

Authors: Thomas Dörner; Vibeke Strand; Gilberto Castañeda-Hernández; Gianfranco Ferraccioli; John D Isaacs; Tore K Kvien; Emilio Martin-Mola; Thomas Mittendorf; Josef S Smolen; Gerd R Burmester
Journal: Ann Rheum Dis Date: 2012-12-19 Impact factor: 19.103

2. Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis.

Authors: John D Isaacs; Stanley B Cohen; Paul Emery; Paul P Tak; Jianmei Wang; Guiyuan Lei; Sarah Williams; Preeti Lal; Simon J Read
Journal: Ann Rheum Dis Date: 2012-06-11 Impact factor: 19.103

3. The need for personalised medicine for rheumatoid arthritis.

Authors: John D Isaacs; Gianfranco Ferraccioli
Journal: Ann Rheum Dis Date: 2010-11-10 Impact factor: 19.103

4. Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register.

Authors: W G Dixon; K L Hyrich; K D Watson; M Lunt; D P M Symmons
Journal: Ann Rheum Dis Date: 2010-05-05 Impact factor: 19.103

Review 5. Therapeutic agents for patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor-alpha antagonists.

Authors: John D Isaacs
Journal: Expert Opin Biol Ther Date: 2009-12 Impact factor: 4.388

6. Rheumatoid arthritis.

Authors: Lars Klareskog; Anca Irinel Catrina; Stephen Paget
Journal: Lancet Date: 2009-01-20 Impact factor: 79.321

7. Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.

Authors: James B Galloway; Louise K Mercer; Alison Moseley; William G Dixon; Andrew P Ustianowski; Matthew Helbert; Kath D Watson; Mark Lunt; Kimme L Hyrich; Deborah Pm Symmons
Journal: Ann Rheum Dis Date: 2012-04-24 Impact factor: 19.103

8. Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.

Authors: Moetaza M Soliman; Darren M Ashcroft; Kath D Watson; Mark Lunt; Deborah P M Symmons; Kimme L Hyrich
Journal: Ann Rheum Dis Date: 2011-02-17 Impact factor: 19.103

9. Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register.

Authors: J B Galloway; K L Hyrich; L K Mercer; W G Dixon; A P Ustianowski; M Helbert; K D Watson; M Lunt; D P M Symmons
Journal: Ann Rheum Dis Date: 2011-07-21 Impact factor: 19.103

10. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial.

Authors: Cem Gabay; Paul Emery; Ronald van Vollenhoven; Ara Dikranian; Rieke Alten; Karel Pavelka; Micki Klearman; David Musselman; Sunil Agarwal; Jennifer Green; Arthur Kavanaugh
Journal: Lancet Date: 2013-03-18 Impact factor: 79.321

4 in total

1. Pim-2/mTORC1 Pathway Shapes Inflammatory Capacity in Rheumatoid Arthritis Synovial Cells Exposed to Lipid Peroxidations.

Authors: Geng Yin; Yan Li; Min Yang; Xiao-min Cen; Qi-bing Xie
Journal: Biomed Res Int Date: 2015-05-04 Impact factor: 3.411